🔥 MIZAR-003 update at #ESMO26: GC101 TIL (no IL-2, low-intensity lymphodepletion) + sintilimab vs chemo, anti-PD-1 refractory melanoma (n=101, randomized phase 2)

🖋️ Lu Si

➡️ mPFS 4.4 vs 1.6 mo, HR 0.44 | ORR 44% vs 8% | G≥3 TRAEs 42% vs 31%
Benefit holds in acral and mucosal

🔍TIL tackling its toxicity problem, plus impressive recruitment and execution in China 🇨🇳 (101 pts randomized in ~15 months)

⚠️ But: open-label, chemo is a soft comparator, mPFS still short

@myESMO @_SEOM @OncoAlert @LARVOL